Asset profile
3BNC117
Monoclonal antibody
Evidence outlook · lead readout
eCLEAR (NCT03041012) · Hiv
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
eCLEAR (NCT03041012): The trial randomly assigned 60 participants to four groups, including standard antiretroviral therapy alone and combinations containing 3BNC117, but treatment was not blinded. Its primary outcomes were virologic and reservoir measures rather than hard clinical outcomes, and the registry provides no results showing whether any primary comparison was met.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 6 direct rivals (same mechanism and indication), 0 same-class, 54 same-indication; 32 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| 3BNC117: this drug | Phase 2 | Monoclonal antibody | HIV envelope | ||
| Teropavimab | Phase 3 | Monoclonal antibody | HIV envelope | ||
| Zinlirvimab | Phase 3 | Monoclonal antibody | HIV envelope | ||
| 10-1074 | Phase 2 | Monoclonal antibody | HIV envelope | ||
| Lotivibart | Phase 2 | Monoclonal antibody | HIV envelope | ||
| BNT351 | Phase 1 | Monoclonal antibody | HIV envelope | ||
| UVAX-1107 | Phase 1 | Vaccine | HIV envelope | ||
| Bictegravir (Biktarvy) | Approved | Small molecule | HIV integrase | ||
| Cabotegravir (Vocabria / Cabenuva / Apretude) | Approved | Small molecule | HIV integrase | ||
| Crofelemer (Mytesi) | Approved | Small molecule | Chloride channel (intestinal epithelium) | ||
| Darunavir (Prezista) | Approved | Small molecule | HIV protease | ||
| Dolutegravir (Tivicay / Triumeq / Dovato / Juluca (component)) | Approved | Small molecule | HIV integrase | ||
| Doravirine (Pifeltro) | Approved | Small molecule | HIV reverse transcriptase | ||
| Elsulfavirine (Elpida) | Approved | Small molecule | HIV reverse transcriptase | ||
| Elvitegravir (Stribild / Genvoya (component)) | Approved | Small molecule | HIV integrase | ||
| Emtricitabine / Tenofovir Disoproxil Fumarate (Truvada) | Approved | Small molecule | HIV reverse transcriptase |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
2027 (1)
July 2027 (1)
2029 (1)
September 2029 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.